Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/a-review-of-immune-mediated-adverse-events-in-melanoma-W1Hd7qCqBF
References (113)
-
M. Delaunay, J. Cadranel, A. Lusque, N. Meyer, Valérie Gounaut, D. Moro-Sibilot, J. Michot, J. Raimbourg, N. Girard, F. Guisier, D. Planchard, A. Metivier, P. Tomasini, É. Dansin, M. Pérol, M. Campana, O. Gautschi, M. Früh, Jean-David Fumet, C. Audigier-Valette, S. Couraud, S. Dalle, M. Leccia, M. Jaffro, S. Collot, G. Prévôt, J. Milia, J. Mazières (2017)
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients, 50
-
N Abdel-Wahab (2018)
10.7326/L18-0209Ann Intern Med, 169
-
J Haanen, F Carbonnel, C Robert (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol., 28
-
J Haanen (2017)
10.1093/annonc/mdx225Ann Oncol., 28
-
H. Läubli, C. Balmelli, M. Bossard, O. Pfister, K. Glatz, A. Zippelius (2015)
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanomaJournal for Immunotherapy of Cancer, 3
-
J. Osorio, A. Ni, J. Chaft, R. Pollina, M. Kasler, Dennis Stephens, Carlos Rodriguez, L. Cambridge, H. Rizvi, J. Wolchok, T. Merghoub, C. Rudin, S. Fish, M. Hellmann, M. Hellmann (2016)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancerAnnals of Oncology, 28
-
A. Shoushtari, C. Friedman, Pedram Navid-Azarbaijani, M. Postow, M. Callahan, P. Momtaz, K. Panageas, J. Wolchok, P. Chapman (2018)
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in MelanomaJAMA Oncology, 4
-
L. Shipman (2016)
Diagnosis: Defining sarcopenia and refining its measurementNature Reviews Rheumatology, 12
-
A. Bertrand, M. Kostine, T. Barnetche, M. Truchetet, T. Schaeverbeke (2015)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisBMC Medicine, 13
-
J. Brahmer, C. Lacchetti, B. Schneider, M. Atkins, Kelly Brassil, J. Caterino, I. Chau, M. Ernstoff, Jennifer Gardner, P. Ginex, S. Hallmeyer, J. Chakrabarty, N. Leighl, J. Mammen, D. McDermott, A. Naing, L. Nastoupil, T. Phillips, Laura Porter, I. Puzanov, C. Reichner, B. Santomasso, Carole Seigel, A. Spira, M. Suarez‐Almazor, Yinghong Wang, J. Weber, J. Wolchok, John Thompson (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 17
-
Frank Cortazar, K. Marrone, M. Troxell, Kenneth Ralto, M. Hoenig, J. Brahmer, D. Le, E. Lipson, I. Glezerman, J. Wolchok, L. Cornell, P. Feldman, M. Stokes, Sarah Zapata, F. Hodi, P. Ott, M. Yamashita, D. Leaf (2016)
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.Kidney international, 90 3
-
J. Delyon, C. Mateus, T. Lambert (2011)
Hemophilia A induced by ipilimumab.The New England journal of medicine, 365 18
-
Arjun Gupta, K. Felice, E. Loftus, S. Khanna (2015)
Systematic review: colitis associated with anti‐CTLA‐4 therapyAlimentary Pharmacology & Therapeutics, 42
-
L. Cappelli, Anna Gutierrez, A. Baer, J. Albayda, R. Manno, U. Haque, E. Lipson, K. Bleich, Ami Shah, J. Naidoo, J. Brahmer, D. Le, C. Bingham (2016)
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabAnnals of the Rheumatic Diseases, 76
-
J. Antoun, C. Titah, I. Cochereau (2016)
Ocular and orbital side-effects of checkpoint inhibitors: a review articleCurrent Opinion in Oncology, 28
-
C. Hua, L. Boussemart, C. Mateus, É. Routier, C. Boutros, H. Cazenave, R. Viollet, Marina Thomas, Séverine Roy, N. Benannoune, G. Tomasic, J. Soria, S. Champiat, M. Texier, E. Lanoy, C. Robert (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.JAMA dermatology, 152 1
-
B. Pellegrino, A. Musolino, M. Tiseo (2017)
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.Annals of oncology : official journal of the European Society for Medical Oncology, 28 6
-
A. Kittai, H. Oldham, J. Cetnar, Matthew Taylor (2017)
Immune Checkpoint Inhibitors in Organ Transplant PatientsJournal of Immunotherapy, 40
-
Vivek Kumar, N. Chaudhary, M. Garg, C. Floudas, P. Soni, A. Chandra (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyFrontiers in Pharmacology, 8
-
C. Lebbé, N. Meyer, L. Mortier, I. Márquez-Rodas, C. Robert, P. Rutkowski, A. Menzies, T. Eigentler, P. Ascierto, M. Smylie, D. Schadendorf, M. Ajaz, I. Svane, R. Gonzalez, L. Rollin, J. Lord-Bessen, A. Saci, E. Grigoryeva, J. Pigozzo (2019)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialJournal of Clinical Oncology, 37
-
Sang Kim, J. Tayar, V. Trinh, M. Suarez‐Almazor, S. García, P. Hwu, Daniel Johnson, M. Uemura, A. Diab (2017)
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case seriesAnnals of the Rheumatic Diseases, 76
-
J Naidoo (2015)
10.1093/annonc/mdv383Ann Oncol, 26
-
P. Diana, Charoen Mankongpaisarnrung, M. Atkins, J. Zeck, A. Charabaty (2018)
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced EnteritisACG Case Reports Journal, 5
-
R. Wanchoo, S. Karam, N. Uppal, V. Barta, G. Deray, C. Devoe, V. Launay-Vacher, K. Jhaveri (2017)
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative ReviewAmerican Journal of Nephrology, 45
-
Megan Pollack, Megan Pollack, A. Betof, H. Dearden, K. Rapazzo, K. Rapazzo, I. Valentine, A. Brohl, K. Ancell, K. Ancell, G. Long, G. Long, G. Long, A. Menzies, A. Menzies, A. Menzies, Z. Eroglu, Douglas Johnson, Douglas Johnson, A. Shoushtari (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanomaAnnals of Oncology, 29
-
S. Hwang, Giuliana Carlos, Deepal Wakade, K. Byth, B. Kong, S. Chou, M. Carlino, R. Kefford, P. Fernández-Peñas (2016)
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.Journal of the American Academy of Dermatology, 74 3
-
C. Friedman, T. Proverbs-Singh, M. Postow (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.JAMA oncology, 2 10
-
Shintaro Iwama, A. Remigis, M. Callahan, S. Slovin, J. Wolchok, P. Caturegli (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking AntibodyScience Translational Medicine, 6
-
J. Naidoo, Xuan Wang, K. Woo, T. Iyriboz, D. Halpenny, J. Cunningham, J. Chaft, N. Segal, M. Callahan, A. Lesokhin, J. Rosenberg, M. Voss, C. Rudin, H. Rizvi, X. Hou, K. Rodriguez, M. Albano, R. Gordon, Charles Leduc, N. Rekhtman, Bianca Harris, A. Menzies, A. Guminski, M. Carlino, B. Kong, J. Wolchok, M. Postow, G. Long, M. Hellmann (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 7
-
J. Weber, F. Hodi, J. Wolchok, S. Topalian, D. Schadendorf, J. Larkin, M. Sznol, G. Long, Hewei Li, I. Waxman, Joel Jiang, C. Robert (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 7
-
L. Riella, A. Paterson, A. Sharpe, A. Chandraker (2012)
Role of the PD‐1 Pathway in the Immune ResponseAmerican Journal of Transplantation, 12
-
J. Villadolid, A. Amin (2015)
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.Translational lung cancer research, 4 5
-
A. Hottinger (2016)
Neurologic complications of immune checkpoint inhibitors.Current Opinion in Neurology
-
L. Spain, S. Diem, J. Larkin (2016)
Management of toxicities of immune checkpoint inhibitors.Cancer treatment reviews, 44
-
S. Lim, Jenny Lee, T. Gide, A. Menzies, A. Guminski, M. Carlino, Edmond Breen, J. Yang, S. Ghazanfar, R. Kefford, R. Scolyer, G. Long, H. Rizos (2018)
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based ImmunotherapyClinical Cancer Research, 25
-
M. Suarez‐Almazor, Sang Kim, N. Abdel-Wahab, A. Diab (2017)
Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of CancerArthritis & Rheumatology, 69
-
T. Tadokoro, Eri Keshino, A. Makiyama, T. Sasaguri, K. Ohshima, H. Katano, M. Mohri (2016)
Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.Circulation. Heart failure, 9 10
-
G. Varricchi, M. Galdiero, G. Marone, Gjada Criscuolo, M. Triassi, D. Bonaduce, G. Marone, C. Tocchetti (2017)
Cardiotoxicity of immune checkpoint inhibitorsESMO Open, 2
-
C. Stroud, A. Hegde, C. Cherry, A. Naqash, N. Sharma, Srikala Addepalli, S. Cherukuri, T. Parent, J. Hardin, P. Walker (2019)
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockadeJournal of Oncology Pharmacy Practice, 25
-
D. Byun, J. Wolchok, L. Rosenberg, M. Girotra (2017)
Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathiesNature Reviews Endocrinology, 13
-
J. Naidoo, D. Page, B. Li, L. Connell, K. Schindler, M. Lacouture, M. Postow, J. Wolchok (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Annals of oncology : official journal of the European Society for Medical Oncology, 27 7
-
W. Vogel, A. Guislain, P. Kvistborg, T. Schumacher, J. Haanen, C. Blank (2012)
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 2
-
J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, P. Rutkowski, J. Grob, L. Cowey, C. Lao, J. Wagstaff, D. Schadendorf, P. Ferrucci, M. Smylie, R. Dummer, A. Hill, D. Hogg, J. Haanen, M. Carlino, O. Bechter, M. Maio, I. Márquez-Rodas, M. Guidoboni, G. McArthur, C. Lebbé, P. Ascierto, G. Long, J. Cebon, J. Sosman, M. Postow, M. Callahan, D. Walker, L. Rollin, R. Bhore, S. Hodi, J. Larkin (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 377
-
K. Esfahani, W. Miller (2017)
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.The New England journal of medicine, 376 20
-
L. Min, F. Hodi, A. Giobbie-Hurder, P. Ott, J. Luke, Hilary Donahue, Meredith Davis, R. Carroll, U. Kaiser (2014)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort StudyClinical Cancer Research, 21
-
J. Brahmer, C. Lacchetti, John Thompson (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.Journal of oncology practice, 14 4
-
Amruth Palla, Devin Kennedy, H. Mosharraf, D. Doll (2016)
Autoimmune Hemolytic Anemia as a Complication of Nivolumab TherapyCase Reports in Oncology, 9
-
S. Cuzzubbo, F. Javeri, M. Tissier, A. Roumi, Ciprian Barlog, J. Doridam, C. Lebbé, C. Belin, R. Ursu, A. Carpentier (2017)
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.European journal of cancer, 73
-
(Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. In: Am soc clin oncol educ book. 2012. p. 174–7.)
Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. In: Am soc clin oncol educ book. 2012. p. 174–7.Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. In: Am soc clin oncol educ book. 2012. p. 174–7., Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. In: Am soc clin oncol educ book. 2012. p. 174–7.
-
Ting Feng, H. Qin, Lanfang Wang, E. Benveniste, C. Elson, Y. Cong (2011)
Th17 Cells Induce Colitis and Promote Th1 Cell Responses through IL-17 Induction of Innate IL-12 and IL-23 ProductionThe Journal of Immunology, 186
-
H. Vallet, A. Gaillet, Nicolas Weiss, C. Vanhaecke, S. Saheb, Valérie Touitou, N. Franck, N. Kramkimel, A. Borden, M. Touat, D. Ricard, M. Verny, T. Maisonobe, D. Psimaras (2016)
Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.Annals of oncology : official journal of the European Society for Medical Oncology, 27 7
-
T. Zhang, S. Fresnay, E. Welty, N. Sangrampurkar, E. Rybak, H. Zhou, X.‐F. Cheng, Q. Feng, C. Avon, A. Laaris, M. Whitters, A. Nagelin, R. Jr, A. Azimzadeh (2011)
Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA‐4‐Dependent MannerAmerican Journal of Transplantation, 11
-
Michael Cook, Chul Kim (2019)
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.JAMA oncology
-
R. Barroso-Sousa, William Barry, A. Garrido-Castro, F. Hodi, L. Min, I. Krop, S. Tolaney (2017)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysisJAMA Oncology, 4
-
Bing Liao, S. Shroff, C. Kamiya-Matsuoka, S. Tummala (2014)
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.Neuro-oncology, 16 4
-
A. Tarhini, H. Zahoor, Yan Lin, U. Malhotra, C. Sander, L. Butterfield, J. Kirkwood (2015)
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanomaJournal for Immunotherapy of Cancer, 3
-
A. Menzies, Douglas Johnson, S. Ramanujam, V. Atkinson, Annie Wong, J. Park, J. McQuade, A. Shoushtari, K. Tsai, Z. Eroglu, O. Klein, Jessica Hassel, J. Sosman, A. Guminski, R. Sullivan, A. Ribas, M. Carlino, M. Davies, S. Sandhu, G. Long (2016)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAnnals of Oncology, 28
-
A. Lomax, H. McGuire, C. McNeil, Clara Choi, P. Hersey, D. Karikios, K. Shannon, S. Hal, Urszula Carr, A. Crotty, S. Gupta, J. Hollingsworth, Haewon Kim, B. Groth, N. McGill (2017)
Immunotherapy‐induced sarcoidosis in patients with melanoma treated with PD‐1 checkpoint inhibitors: Case series and immunophenotypic analysisInternational Journal of Rheumatic Diseases, 20
-
P. Caturegli, G. Dalmazi, M. Lombardi, F. Grosso, H. Larman, Tatianna Larman, G. Taverna, M. Cosottini, I. Lupi (2016)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.The American journal of pathology, 186 12
-
I. Puzanov, A. Diab, K. Abdallah, C. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. Lacouture, N. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. Silk, D. Skondra, M. Suarez‐Almazor, Y. Wang, K. Wiley, H. Kaufman, M. Ernstoff, Jeff Chen, J. Anderson, Deborah Arrindell, S. Andrews, J. Ballesteros, J. Boyer, Daniel Chen, David Chonzi, I. Cotarla, R. Cunha, M. Davies, M. Dawson, A. Dicker, L. Eifler, Andrew Ferguson, C. Ferlini, S. Frankel, W. Go, Celestine Gochett, J. Goldberg, P. Goncalves, T. Goswami, Nancy Gregory, J. Gulley, V. Hayreh, Nicole Helie, William Holmes, J. hsu, R. Ibrahim, C. Larocca, K. Lehman, S. Ley-Acosta, O. Lambotte, J. Luke, J. Mcclure, E. Michelon, Mary Nakamura, K. Patel, B. Piperdi, Z. Rasheed, D. Reshef, J. Riemer, C. Robert, M. Sarkeshik, Ann Saylors, J. Schreiber, K. Shafer-Weaver, W. Sharfman, E. Sharon, R. Sherry, C. Simonson, C. Thomas, John Thompson, E. Trehu, D. Tresnan, M. Turner, Darshan Wariabharaj, I. Waxman, L. Wood, Lin Zhang, P. Zheng (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupJournal for Immunotherapy of Cancer, 5
-
A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer, J. Wolchok, H. Schmidt, O. Hamid, C. Robert, P. Ascierto, J. Richards, C. Lebbé, V. Ferraresi, M. Smylie, J. Weber, M. Maio, L. Bastholt, L. Mortier, L. Thomas, S. Tahir, A. Hauschild, Jessica Hassel, F. Hodi, C. Taitt, V. Pril, G. Schaetzen, S. Suciu, A. Testori (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.The New England journal of medicine, 375 19
-
J. Naidoo, L. Cappelli, P. Forde, K. Marrone, E. Lipson, H. Hammers, W. Sharfman, D. Le, A. Baer, Ami Shah, J. Albayda, R. Manno, U. Haque, Anna Gutierrez, C. Bingham, J. Brahmer (2017)
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeThe Oncologist, 22
-
John Thompson (2018)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.Journal of the National Comprehensive Cancer Network : JNCCN, 16 5S
-
Yucai Wang, Shouhao Zhou, Fang Yang, Xinyue Qi, Xin Wang, X. Guan, Chan Shen, N. Duma, J. Aguilera, A. Chintakuntlawar, K. Price, J. Molina, L. Pagliaro, T. Halfdanarson, A. Grothey, S. Markovic, G. Nowakowski, S. Ansell, Michael Wang (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.JAMA oncology
-
H. Helgadottir, L. Kis, P. Ljungman, P. Ljungman, James Larkin, R. Kefford, P. Ascierto, Johan Hansson, G. Masucci (2017)
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.Annals of oncology : official journal of the European Society for Medical Oncology, 28 7
-
Jonathan Chen, Maryam Pezhouh, G. Lauwers, Ricard Masia (2017)
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 AntibodiesThe American Journal of Surgical Pathology, 41
-
J. Weber (2012)
Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
-
P. Ascierto, M. Vecchio, C. Robert, A. Mackiewicz, V. Chiarion-Sileni, A. Arance, C. Lebbé, L. Bastholt, O. Hamid, P. Rutkowski, C. McNeil, C. Garbe, C. Loquai, B. Dréno, L. Thomas, J. Grob, G. Liszkay, M. Nyakas, R. Gutzmer, J. Pikiel, F. Grange, C. Hoeller, V. Ferraresi, M. Smylie, D. Schadendorf, L. Mortier, I. Svane, D. Hennicken, A. Qureshi, M. Maio (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.The Lancet. Oncology, 18 5
-
Lindsey Collins, M. Chapman, M. Chapman, Joi Carter, Joi Carter, F. Samie, F. Samie (2017)
Cutaneous adverse effects of the immune checkpoint inhibitors.Current problems in cancer, 41 2
-
R. Belkhir, S. Burel, L. Dunogeant, A. Marabelle, A. Hollebecque, B. Besse, A. Leary, A. Voisin, C. Pontoizeau, L. Coutte, E. Pertuiset, G. Mouterde, O. Fain, O. Lambotte, X. Mariette (2017)
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatmentAnnals of the Rheumatic Diseases, 76
-
V. Belum, B. Benhuri, M. Postow, M. Hellmann, A. Lesokhin, N. Segal, R. Motzer, S. Wu, K. Busam, J. Wolchok, M. Lacouture (2016)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.European journal of cancer, 60
-
C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J. Hassel, P. Rutkowski, C. McNeil, E. Kalinka‐Warzocha, K. Savage, M. Hernberg, C. Lebbé, J. Charles, C. Mihalcioiu, V. Chiarion-Sileni, C. Mauch, F. Cognetti, A. Arance, H. Schmidt, D. Schadendorf, H. Gogas, L. Lundgren-Eriksson, C. Horak, B. Sharkey, I. Waxman, V. Atkinson, P. Ascierto (2015)
Nivolumab in previously untreated melanoma without BRAF mutation.The New England journal of medicine, 372 4
-
K. Chmiel, D. Suan, C. Liddle, B. Nankivell, R. Ibrahim, C. Bautista, J. Thompson, D. Fulcher, R. Kefford (2011)
Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 9
-
E. Shiuan, K. Beckermann, A. Ozgun, C. Kelly, M. McKean, J. McQuade, M. Thompson, I. Puzanov, J. Greer, Suthee Rapisuwon, M. Postow, M. Davies, Z. Eroglu, Douglas Johnson (2017)
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapyJournal for Immunotherapy of Cancer, 5
-
D. Morganstein, Z. Lai, L. Spain, S. Diem, D. Levine, C. Mace, M. Gore, J. Larkin (2017)
Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanomaClinical Endocrinology, 86
-
B. Kong, K. Micklethwaite, S. Swaminathan, R. Kefford, M. Carlino (2016)
Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.Melanoma research, 26 2
-
V. Velu, R. Shetty, M. Larsson, E. Shankar (2015)
Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic optionsRetrovirology, 12
-
Douglas Johnson, R. Sullivan, P. Ott, M. Carlino, N. Khushalani, Fei Ye, A. Guminski, I. Puzanov, D. Lawrence, E. Buchbinder, Tejaswi Mudigonda, K. Spencer, C. Bender, Jenny Lee, H. Kaufman, A. Menzies, J. Hassel, J. Mehnert, J. Sosman, G. Long, Joseph Clark (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.JAMA oncology, 2 2
-
J. Wolchok, B. Neyns, G. Linette, S. Négrier, J. Lutzky, L. Thomas, W. Waterfield, D. Schadendorf, M. Smylie, T. Guthrie, J. Grob, J. Chesney, K. Chin, Kun Chen, A. Hoos, S. O'Day, C. Lebbé (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.The Lancet. Oncology, 11 2
-
10.14694/EdBook_AM.2012.32.79
-
Mabel Ryder, M. Callahan, M. Postow, J. Wolchok, J. Fagin (2014)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.Endocrine-related cancer, 21 2
-
L. Shipman (2016)
Rheumatoid arthritis: Tocilizumab and the risk of intestinal perforationNature Reviews Rheumatology, 12
-
Jean-Marie Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel, S. Postel-Vinay, A. Berdelou, A. Varga, R. Bahleda, A. Hollebecque, C. Massard, A. Fuerea, V. Ribrag, A. Gazzah, J. Armand, N. Amellal, E. Angevin, N. Noel, C. Boutros, C. Mateus, C. Robert, J. Soria, A. Marabelle, O. Lambotte (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.European journal of cancer, 54
-
T. Uldrick, P. Goncalves, M. Abdul-Hay, A. Claeys, B. Emu, M. Ernstoff, S. Fling, L. Fong, J. Kaiser, Andreanne Lacroix, Steve Lee, Lisa Lundgren, K. Lurain, Christopher Parsons, Sharavi Peeramsetti, R. Ramaswami, E. Sharon, M. Sznol, C. Wang, R. Yarchoan, M. Cheever (2019)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.JAMA oncology
-
J. Weber, R. Dummer, V. Pril, C. Lebbé, F. Hodi (2013)
Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumabCancer, 119
-
L. Cappelli, Anna Gutierrez, C. Bingham, Ami Shah (2017)
Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the LiteratureArthritis Care & Research, 69
-
D. Palmieri, M. Carlino (2018)
Immune Checkpoint Inhibitor ToxicityCurrent Oncology Reports, 20
-
Katsunori Tanaka, M. Albin, Xueli Yuan, K. Yamaura, A. Habicht, T. Murayama, M. Grimm, A. Waaga, T. Ueno, R. Padera, H. Yagita, M. Azuma, T. Shin, B. Blazar, D. Rothstein, M. Sayegh, N. Najafian (2007)
PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection1The Journal of Immunology, 179
-
L. Heinzerling, P. Ott, F. Hodi, A. Husain, Azadeh Tajmir-Riahi, H. Tawbi, M. Pauschinger, T. Gajewski, E. Lipson, J. Luke (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapyJournal for Immunotherapy of Cancer, 4
-
P. Lurz, I. Eitel, J. Adam, J. Steiner, M. Grothoff, S. Desch, G. Fuernau, S. Waha, M. Sareban, Christian Luecke, K. Klingel, R. Kandolf, G. Schuler, M. Gutberlet, H. Thiele (2012)
Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis.JACC. Cardiovascular imaging, 5 5
-
I. Mellman, G. Coukos, G. Dranoff (2011)
Cancer immunotherapy comes of ageNature, 480
-
Douglas Johnson, J. Balko, Margaret Compton, S. Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, I. Puzanov, Matthew Alexander, Tyler Bloomer, J. Becker, D. Slosky, E. Phillips, M. Pilkinton, Laura Craig-Owens, Nina Kola, G. Plautz, D. Reshef, Jonathan Deutsch, R. Deering, B. Olenchock, A. Lichtman, D. Roden, C. Seidman, I. Koralnik, J. Seidman, R. Hoffman, J. Taube, Luis Diaz, R. Anders, J. Sosman, J. Moslehi (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.The New England journal of medicine, 375 18
-
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, Jessica Hassel, W. Akerley, A. Eertwegh, J. Lutzky, P. Lorigan, Julia Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba (2010)
Improved survival with ipilimumab in patients with metastatic melanoma.The New England journal of medicine, 363 8
-
Toshiro Ito, Takuya Ueno, M. Clarkson, Xueli Yuan, Mollie Jurewicz, Hideo Yagita, M. Azuma, Arlene Sharpe, Hugh Auchincloss, M. Sayegh, N. Najafian (2005)
Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo1The Journal of Immunology, 174
-
M. Postow, R. Sidlow, M. Hellmann (2018)
Immune‐Related Adverse Events Associated with Immune Checkpoint BlockadeThe New England Journal of Medicine, 378
-
Roberto Zanetti, L. Sacchetto, Stefano Rosso (2018)
Scrutiny-Dependent Cancer and Self-fulfilling Risk FactorsAnnals of Internal Medicine, 169
-
Viktoria Bergqvist, E. Hertervig, Peter Gedeon, Marija Kopljar, H. Griph, S. Kinhult, A. Carneiro, J. Marsal (2017)
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitisCancer Immunology, Immunotherapy, 66
-
M. Heppt, M. Schlaak, T. Eigentler, K. Kähler, F. Kiecker, C. Loquai, F. Meier, D. Tomsitz, N. Brenner, A. Niesert, R. Thonke, A. Hauschild, C. Berking (2017)
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.Annals of oncology : official journal of the European Society for Medical Oncology, 28 12
-
M. Sznol, M. Postow, M. Davies, A. Pavlick, E. Plimack, M. Shaheen, Colleen Veloski, C. Robert (2017)
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.Cancer treatment reviews, 58
-
C. Robert, J. Schachter, G. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, O. Hamid, C. Mateus, R. Shapira-Frommer, M. Kosh, Honghong Zhou, N. Ibrahim, S. Ebbinghaus, A. Ribas (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.The New England journal of medicine, 372 26
-
J. Sun, J. Schiffman, A. Raghunath, D. Tang, Hong Chen, P. Sharma (2008)
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.Cancer immunity, 8
-
N Abdel-Wahab, M Shah, MA Lopez-Olivo, ME Suarez-Almazor (2018)
Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune diseaseAnn Intern Med, 169
-
D. Pardoll (2012)
The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 12
-
J. Weber, J. Yang, M. Atkins, M. Disis (2015)
Toxicities of Immunotherapy for the Practitioner.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 18
-
C. Gay, R. Bosch, J. Ritz, J. Hataye, E. Aga, R. Tressler, S. Mason, C. Hwang, D. Grasela, N. Ray, J. Cyktor, J. Coffin, E. Acosta, R. Koup, J. Mellors, J. Eron (2017)
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral TherapyThe Journal of Infectious Diseases, 215
-
P. Cramer, R. Bresalier (2017)
Gastrointestinal and Hepatic Complications of Immune Checkpoint InhibitorsCurrent Gastroenterology Reports, 19
-
M. González-Cao, T. Morán, J. Dalmau, J. García-Corbacho, R. Bernabé, Ó. Juan, J. Castro, R. Blanco, A. Meyerhans, J. Blanco, N. Karachaliou, C. Brander, J. García-Prado, J. Carrillo, M. Provencio, M. Vila, B. Massutí, B. Clotet, J. Martinez-Picado, R. Rosell (2019)
Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.Journal of Clinical Oncology
-
J. Weber, John Thompson, O. Hamid, D. Minor, A. Amin, I. Ron, R. Ridolfi, H. Assi, A. Maraveyas, D. Berman, J. Siegel, S. O'Day (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV MelanomaClinical Cancer Research, 15
-
M. Touat, Daniel Talmasov, D. Ricard, D. Psimaras (2017)
Neurological toxicities associated with immune-checkpoint inhibitorsCurrent Opinion in Neurology, 30
-
E. Byrne, D. Fisher (2017)
Immune and molecular correlates in melanoma treated with immune checkpoint blockadeCancer, 123
-
G. Long, G. Long, V. Atkinson, V. Atkinson, J. Cebon, M. Jameson, B. Fitzharris, C. McNeil, A. Hill, A. Ribas, M. Atkins, John Thompson, W. Hwu, F. Hodi, A. Menzies, A. Menzies, A. Guminski, A. Guminski, R. Kefford, Benjamin Kong, Benjamin Kong, B. Tamjid, A. Srivastava, A. Lomax, Mohammed Islam, X. Shu, S. Ebbinghaus, N. Ibrahim, M. Carlino, M. Carlino (2017)
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.The Lancet. Oncology, 18 9
-
J. Weber, K. Kähler, A. Hauschild (2012)
Management of immune-related adverse events and kinetics of response with ipilimumab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
-
Brock McMillen, M. Dhillon, Sabrina Yong-Yow (2016)
A rare case of thyroid stormBMJ Case Reports, 2016
- Publisher
- Springer Journals
- Copyright
- Copyright © 2019 by The Author(s)
- Subject
- Medicine & Public Health; Internal Medicine
- ISSN
- 2366-1070
- eISSN
- 2366-1089
- DOI
- 10.1007/s40487-019-0096-8
- Publisher site
- See Article on Publisher Site
Abstract
The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system can lead to a unique constellation of side effects, distinct from other cancer therapies, collectively termed immune-mediated adverse events (irAEs). This review will focus on irAEs and guidelines for management related to the most clinically relevant checkpoint inhibitors, those that target programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4).
Journal
Oncology and Therapy – Springer Journals
Published: Jul 8, 2019